Results 171 to 180 of about 20,828 (198)
First-line treatment strategies for <i>BRAF</i>-V600E mutated non-small cell lung cancer: lessons from real-world data and ongoing uncertainties. [PDF]
J Thorac DisZannini I, De Giglio A.
europepmc +1 more source
Systemic treatment for a young patient with stage IV melanoma: A case report. [PDF]
Oncol LettHuang X, Zhao L, Wang P, Xue D.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2014
Dabrafenib was developed as a highly specific reversible inhibitor of V600-mutant BRAF kinase, an oncogenic mutation driving proliferation in many different types of aggressive tumors. Metastatic melanoma has a high prevalence of V600-mutant BRAF, and clinical trials showed that dabrafenib improved response rates and median progression-free survival in
Radhika, Kainthla +2 more
+5 more sources
Dabrafenib was developed as a highly specific reversible inhibitor of V600-mutant BRAF kinase, an oncogenic mutation driving proliferation in many different types of aggressive tumors. Metastatic melanoma has a high prevalence of V600-mutant BRAF, and clinical trials showed that dabrafenib improved response rates and median progression-free survival in
Radhika, Kainthla +2 more
+5 more sources